Navigation Links
MabPlex International Announces Appointment of Dr. Wei Chen (Ph.D) as Chief Executive Officer
Date:6/11/2019

MabPlex International Ltd (MabPlex), a leading and fully integrated global Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and the United States, today announced the appointment of Wei Chen, Ph.D as the company's new Chief Executive Officer (CEO). Dr Chen will be responsible for the company's strategic planning and operations management.

“I am very pleased that Dr. Chen has joined MabPlex. He is a senior biopharmaceutical executive and has participated in the development of many novel therapeutic agents. Dr. Chen has extensive experience in the R&D, operation and management of large-scale biopharmaceutical manufacturing projects, and he will, no doubt, strengthen the overall strategy, service and management of our Chemistry, Manufacturing and Controls (CMC) operations," said Jianmin Fang, Ph.D, Chairman of MabPlex.

“MabPlex is a CDMO service company specializing in bio-macro molecules offering an integrated service platform that is unique in our industry,” said Dr. Wei Chen. “It is one of the few platforms globally with high production capacity, a world class team, and diverse project experience in Asia and abroad. I am excited to lead MabPlex’s expansion and work with the company's seasoned team to further grow a world-class CDMO platform. Together we will continue to evolve and provide practical and reliable assistance to many biopharmaceutical companies and help them accelerate the development and launch of their novel drugs,” Chen concluded.

Extensive experience
Dr. Chen has more than three decades of experience in building large-scale biomanufacturing platforms for global biopharmaceutical companies as well as establishing quality management systems, new product development and global regulatory submissions.

Before joining MabPlex, Dr. Chen was responsible for new pharmaceutical/ biopharmaceutical development and manufacturing scale-up at Bristol-Myers Squibb (BMS) and Johnson & Johnson (J&J). He also served as Chief Executive Officer (CEO), Chief Scientific Officer (CSO) and held other senior management positions at companies including Immunomedics and Phage Pharmaceuticals.

Dr. Chen was involved in the development and scale-up of several biopharmaceuticals, including the first TNF-a antibody product approved in Europe and United States, an early anti-tumor antibody-drug conjugate (ADC), a humanized monoclonal antibody inhibiting tumor growth, and a series of novel biologics, including a platelet aggregation inhibitor used during and after coronary artery procedures.

Dr. Chen has also played a key role in managing a number of startup biotech companies, bringing them from proof of concept to late stage clinical development and IPO. He led the internationally renowned CDMO company BioReliance, and managed this company's initial operations.

Finally, Dr. Chen served as Chief of Chemistry, Manufacturing and Controls (CMC) and Vice President of Manufacturing at BioAtla, the world's leading Conditionally Active Biologics™ (CAB) ADC drug development company.

About MabPlex
MabPlex, a leading and fully integrated Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global biopharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing. With our state-of-the-art facilities and exemplary biologics development and manufacturing experience, MabPlex commits to being a valuable partner for our clients around the globe.

Read the full story at https://www.prweb.com/releases/mabplex_international_announces_appointment_of_dr_wei_chen_ph_d_as_chief_executive_officer/prweb16364693.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
2. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
3. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
4. IsoRay Announces A New International Distributor For Greece
5. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
6. PAREXEL International To Present At Jefferies Healthcare Conference
7. Clinical Team Researching the Impact of the EarlySense System Wins Best Novel Idea Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference
8. Israel Brain Technologies Announces Israels 1st International Brain Technology Conference
9. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
10. DMH International Announces EMR Integration to TouchPACS
11. MEDIFIRST SOLUTIONS, INC. To Exhibit At The Orlando International Beauty Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... ... June 15, 2019 , ... Lycotec Ltd, ... a clinical study on its new prebiotic, LycoBiotic™, which is 1,000 – 4,000 ... chocolate formulations, which were based on a proprietary composition of GA lycopene, specially ...
(Date:6/14/2019)... , ... June 14, 2019 , ... Land O' ... announce the release of their new website designed to help patients obtain useful information, ... , Land O’ Lakes, Florida Chiropractor, Dr. Michael Craven is committed to ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... a front desk employee with a back problem, underscore the responsibility of employers ... XpertHR explores which employee accommodation requests are reasonable and which are not - ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... ... in Obstetrics and Gynecology specializes in pelvic pain treatment for women. Pelvic pain can ... Excellence handles routine and complicated pelvic pain conditions including:, , Uterine ... , Adhesions (scar tissue) , Interstitial Cystitis , ...
(Date:6/13/2019)... ... June 13, 2019 , ... In Partnership with the ... services for low-income, underinsured individuals at its Mesquite, TX office on July 13th. , ... cleanings and extractions . For more information, please visit the ...
(Date:6/13/2019)... ... , ... Hard money lenders like Monroe Funding Corporation are able to respond ... provided quickly. If the documentation and collateral are immediately available, it’s possible to receive ... oversight involved with a traditional lender, which allows loans to be customized and adjusted ...
(Date:6/13/2019)... ... 13, 2019 , ... In two nationally representative surveys of parents and principals ... impact movement Active Schools aimed to gain a better understanding of ... , The U.S. Department of Health and Human Services recommends that children and ...
(Date:6/13/2019)... ... June 13, 2019 , ... Clinical Ink , a global clinical trial ... Jonathan Andrus , chief business officer at Clinical Ink, has been invited to ... Health Policy on July 1, 2019, in Washington, D.C. The workshop, convened under ...
Breaking Medicine News(10 mins):